US2004265287A1PendingUtilityA1

Myocardial grafts and cellular compositions useful for same

53
Priority: Nov 16, 1993Filed: May 18, 2004Published: Dec 30, 2004
Est. expiryNov 16, 2013(expired)· nominal 20-yr term from priority
Inventors:Loren J. Field
A01K 2217/05A61K 35/34A01K 67/0271C12N 2506/02C12N 2500/22C12N 2517/02C12N 5/0658A61K 35/12C12N 2510/00A61K 48/00C07K 14/4716C12N 5/0657
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described are preferred myocardial grafts of skeletal myoblasts or cardiomyocytes, and cellular compositions and methods useful in obtaining the grafts. The myocardial grafts are stable and can be used, for example, to deliver recombinant proteins directly to the heart.

Claims

exact text as granted — not AI-modified
1 - 25 . (canceled)  
     
     
         26 . A method of treating diseased or damaged myocardial tissue comprising forming a cellular graft in said tissue, wherein said cellular graft contains skeletal myoblasts, skeletal myocytes derived from the skeletal myoblasts, or a combination thereof, and wherein the graft is viable for at least six months.  
     
     
         27 . A method for treating diseased or damaged tissue according to  claim 26 , wherein the animal is a mammal.  
     
     
         28 . A method for treating diseased or damaged tissue according to  claim 27 , wherein the myocardial tissue is infarcted tissue.  
     
     
         29 . A method for treating diseased or damaged tissue according to  claim 27 , wherein the myocardial tissue is ventricular myocardial tissue.  
     
     
         30 . A method for treating diseased or damaged tissue according to  claim 29 , wherein the myocardial tissue is left ventricular myocardial tissue.  
     
     
         31 . A method for treating diseased or damaged tissue according to  claim 26 , wherein the engrafted cells are substantially non-immunogenic to the animal.  
     
     
         32 . A method for treating diseased or damaged tissue according to  claim 26 , wherein the engrafted cells carry a transgene encoding a recombinant molecule.  
     
     
         33 . A method for treating diseased or damaged tissue according to  claim 32 , wherein the recombinant molecule is a protein.  
     
     
         34 . A method for treating diseased or damaged tissue according to  claim 33 , wherein the protein is delivered to the myocardial tissue by the engrafted cells.  
     
     
         35 . A method for treating diseased or damaged tissue according to  claim 34 , wherein the protein is an angiogenic factor or neurotrophic agent.  
     
     
         36 . A method for treating diseased or damaged tissue according to  claim 35 , wherein the protein is an angiogenic factor that induces neovascularization in the myocardial tissue.  
     
     
         37 . A method for treating diseased or damaged tissue according to  claim 36 , wherein the angiogenic factor is basic or acidic Fibroblast Growth Factor, Transforming Growth Factor-Beta, Vascular Endothelial Growth Factor, or Hepatocyte Growth Factor.  
     
     
         38 . A method for treating diseased or damaged tissue according to  claim 35 , wherein the protein is a neurotrophic agent.  
     
     
         39 . A method for treating infarcted myocardial tissue in an animal, comprising forming a cellular graft in said tissue, wherein said cellular graft contains skeletal myoblasts, skeletal myocytes derived from the skeletal myoblasts, or a combination thereof.  
     
     
         40 . A method for treating infarcted myocardial tissue of  claim 39 , wherein the myocardial tissue is ventricular myocardial tissue.  
     
     
         41 . A method for treating infarcted myocardial tissue of  claim 40 , wherein the myocardial tissue is left ventricular myocardial tissue.  
     
     
         42 . A method for treating infarcted myocardial tissue of  claim 40 , wherein the animal is a mammal.  
     
     
         43 . A method for treating infarcted myocardial tissue of  claim 41 , wherein the animal is a mammal.

Join the waitlist — get patent alerts

Track US2004265287A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.